n (%) | Placebo (n=41) | Clazakizumab 25 mg (n=41) | Clazakizumab 100 mg (n=42) | Clazakizumab 200 mg (n=41) |
Week 16 | ||||
PASI 75 | 6 (14.6) | 5 (12.2) | 7 (16.7) | 2 (4.9) |
PASI 50 | 15 (36.6) | 14 (34.1) | 13 (31.0) | 8 (19.5) |
Week 24 | ||||
PASI 75 | 5 (12.2) | 8 (19.5) | 12 (28.6) | 5 (12.2) |
PASI 50 | 12 (29.3) | 17 (41.5) | 16 (38.1) | 10 (24.4) |
PASI, psoriasis area severity index.